Active Not Recruiting OBSERVATIONAL NCT07154810
Observational Study to Evaluate Long Term Outcomes for Ocular Hypertension and Glaucoma Patients Treated With the SpyGlass Bimatoprost Implant System / IOL Combination
Observational Study to Evaluate Long-term Follow-up of Subjects Implanted With Sustained-release Bimatoprost With the SpyGlass IOL in Subjects With Ocular Hypertension or Mild-to-moderate Open-angle Glaucoma
Sponsor: SpyGlass Pharma, Inc.
Conditions
Cataract Glaucoma Ocular Hypertension
Updated 1 time since 2025 Last updated: Aug 26, 2025 Started: Mar 16, 2023 Primary completion: Apr 14, 2031 Completion: Apr 14, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
Listed as NCT07154810, this observational or N/A phase trial focuses on Cataract and Glaucoma and remains ongoing. Sponsored by SpyGlass Pharma, Inc., it has been updated 1 time since 2023, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.
Status Flow
Change History
1 version recorded Active Not Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- SpyGlass Pharma, Inc.
Data source: SpyGlass Pharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .